BIRC2 and neoplasm: Applying a second mitochondria-derived activator of caspase (SMAC) mimetic degrading both Baculoviral IAP repeat-containing protein 2 (BIRC2) and BIRC3, which target the TRAF2 interaction partner cellular inhibitor of apoptosis protein 1 (cIAP1), restored sensitivity to ICBT in several preclinical tumour models [101].